Drug
HEC585
HEC585 is a pharmaceutical drug with 5 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
2(40%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
3
60%
Ph phase_3
1
20%
Ph phase_2
1
20%
Phase Distribution
3
Early Stage
1
Mid Stage
1
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
3(60.0%)
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
1(20.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
5
all time
Status Distribution
Active(2)
Completed(3)
Detailed Status
Completed3
Recruiting1
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
2
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 13 (60.0%)
Phase 21 (20.0%)
Phase 31 (20.0%)
Trials by Status
completed360%
recruiting120%
active_not_recruiting120%
Recent Activity
2 active trials
Showing 5 of 5
recruitingphase_3
Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF
NCT07082842
active_not_recruitingphase_2
Phase ll Study of HEC585 in Patients With IPF
NCT05060822
completedphase_1
To Evaluate Drug-drug Interactions Between HEC585 and Pirfenidone or Nintedanib in Healthy Volunteers
NCT05383131
completedphase_1
Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC585 in Healthy Male and Female Subjects
NCT04512170
completedphase_1
The Safety, Tolerability and Pharmacokinetic Study of HEC585 in Healthy Male and Female Subjects
NCT03092102
Clinical Trials (5)
Showing 5 of 5 trials
NCT07082842Phase 3
Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF
NCT05060822Phase 2
Phase ll Study of HEC585 in Patients With IPF
NCT05383131Phase 1
To Evaluate Drug-drug Interactions Between HEC585 and Pirfenidone or Nintedanib in Healthy Volunteers
NCT04512170Phase 1
Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC585 in Healthy Male and Female Subjects
NCT03092102Phase 1
The Safety, Tolerability and Pharmacokinetic Study of HEC585 in Healthy Male and Female Subjects
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5